We are comparing two treatment options for low-risk, triple-negative early breast cancer to see which is more effective. The study also evaluates how these treatments affect patients' quality of life.
Health conditions and diseases that the clinical trial is designed to study and treat.
Triple-negative breast cancer (TNBC) is a type of breast cancer that does not have any of the three common receptors known to fuel most breast cancer growth—estrogen, progesterone, and the HER-2/neu gene. This makes it more challenging to treat, as it does not respond to hormonal therapy or therapies that target HER-2.
These questions help us understand your situation so we can let the trial team know whether you might be a potential match. This is not a medical evaluation and is not part of the official screening, the study doctor will make the final decision..
Locations and medical facilities where this clinical trial is currently recruiting or conducting research. Select the locations where you would like to participate.
Disclaimer: Parts of this content have been automatically extracted from the EU Clinical Trials registry. While we strive for accuracy, please always contact the trial site or sponsor directly for correct and official information before making any decisions about participation. View on EU Clinical Trials.